Edesa Biotech (EDSA) Reports Phase 3 Success for ARDS Drug, $7.2M FY2025 Loss
Edesa Biotech (EDSA) disclosed Phase 3 success for paridiprubart in ARDS and a $7.2M net loss for FY2025 in an 8-K filing.
CDT Equity Inc. (CDT) Sells Subsidiary Conduit Pharmaceuticals for $7 Million
CDT Equity Inc. (CDT) sold its subsidiary Conduit Pharmaceuticals Limited to Corvus Capital Limited for $7 million, according to an SEC 8-K filing.
Century Therapeutics (IPSC) Reports Positive Clinical Data for Three Pipeline Candidates in Autoimmune and Diabetes Programs
Century Therapeutics (IPSC) disclosed positive Phase 1/2 data for CNTY-101 and preclinical progress for CNTY-813 and CNTY-308 in an SEC 8-K filing.
ProPhase Labs (PRPH) Implements 1-for-10 Reverse Stock Split to Meet Listing Standards
ProPhase Labs (PRPH) executed a 1-for-10 reverse stock split effective December 22, 2025, to regain compliance with Nasdaq listing requirements.
BioCryst Pharmaceuticals (BCRX) Gains FDA Approval for ORLADEYO Pediatric Formulation
BioCryst Pharmaceuticals (BCRX) announced FDA approval of ORLADEYO oral pellets for pediatric HAE patients aged 2 to <12 years.